O
OrbiMed Portfolio holdings
AUM
$3.98B
1-Year Return
13.05%
This Quarter Return
+2.22%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.05B
AUM Growth
-$173M
(-3.3%)
Cap. Flow
-$29.7M
Cap. Flow
% of AUM
-0.59%
Top 10 Holdings %
Top 10 Hldgs %
35.6%
Holding
132
New
17
Increased
26
Reduced
29
Closed
15
Top Buys
| 1 |
Enliven Therapeutics
ELVN
|
$173M |
| 2 |
Biogen
BIIB
|
$68.6M |
| 3 |
Eli Lilly
LLY
|
$63.9M |
| 4 |
Baxter International
BAX
|
$63.4M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$60M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$117M |
| 2 |
Pfizer
PFE
|
$71.4M |
| 3 |
Natera
NTRA
|
$54M |
| 4 |
UnitedHealth
UNH
|
$49.4M |
| 5 |
89bio
ETNB
|
$46.6M |
Sector Composition
| 1 | Healthcare | 97.56% |
| 2 | Industrials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Apellis Pharmaceuticals
APLS
$3.51B
| $60M | 1.18% |
+910,200
| New | +$60M |
|
27
SI-BONE Inc
SIBN
$708M
| $57.4M | 1.13% |
2,919,454
-448,546
| -13% | -$8.82M |
|
28
Prelude Therapeutics
PRLD
$65.1M
| $57.2M | 1.12% |
10,039,691
| – | – |
|
29
ARS Pharmaceuticals
SPRY
$1.03B
| $56.9M | 1.12% |
8,740,887
| – | – |
|
30
Vertex Pharmaceuticals
VRTX
$101B
| $56M | 1.1% |
177,600
-93,900
| -35% | -$29.6M |
|
|
31
Natera
NTRA
$23.1B
| $54.1M | 1.06% |
973,581
-972,772
| -50% | -$54M |
|
32
Edwards Lifesciences
EW
$47.4B
| $52.1M | 1.02% |
630,000
-230,500
| -27% | -$19.1M |
|
33
scPharmaceuticals
SCPH
$299M
| $50.4M | 0.99% |
5,559,528
| – | – |
|
34
Neurocrine Biosciences
NBIX
$13.7B
| $49.5M | 0.97% |
489,000
-198,700
| -29% | -$20.1M |
|
35
Disc Medicine
IRON
$2.09B
| $48.1M | 0.94% |
2,269,637
+108,696
| +5% | +$2.3M |
|
|
KDNY
36
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $47M | 0.92% |
2,029,300
| – | – |
|
37
Xtant Medical Holdings
XTNT
$80.8M
| $46.6M | 0.92% |
73,114,592
| – | – |
|
|
VECT
38
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $43.9M | 0.86% |
5,156,561
-1,850,300
| -26% | -$15.7M |
|
39
Adicet Bio
ACET
$60.4M
| $42.9M | 0.84% |
7,447,140
| – | – |
|
40
uniQure
QURE
$954M
| $41.6M | 0.82% |
2,064,455
+316,900
| +18% | +$6.38M |
|
41
Xenon Pharmaceuticals
XENE
$2.97B
| $41.1M | 0.81% |
1,149,100
| – | – |
|
42
Travere Therapeutics
TVTX
$1.83B
| $39.2M | 0.77% |
1,744,300
+491,170
| +39% | +$11M |
|
43
Mersana Therapeutics
MRSN
$34.6M
| $37M | 0.73% |
360,457
| – | – |
|
|
BLU
44
DELISTED
BELLUS Health Inc.
BLU
| $36.8M | 0.72% |
5,108,900
+400,000
| +8% | +$2.88M |
|
45
Syndax Pharmaceuticals
SNDX
$1.38B
| $36.2M | 0.71% |
1,711,675
-294,825
| -15% | -$6.23M |
|
46
Janux Therapeutics
JANX
$1.42B
| $34.3M | 0.67% |
2,836,386
| – | – |
|
|
MRTX
47
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $34M | 0.67% |
913,650
-370,042
| -29% | -$13.8M |
|
48
Progyny
PGNY
$2.02B
| $33.3M | 0.65% |
1,037,912
+2,912
| +0.3% | +$93.5K |
|
49
Repare Therapeutics
RPTX
$72.6M
| $32.7M | 0.64% |
3,322,488
| – | – |
|
50
TELA Bio
TELA
$63.4M
| $32.2M | 0.63% |
3,027,542
| – | – |
|